INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND INNOVATIVE STUDIES
ISSN: 2820-7157
www.ijsrisjournal.com

August 2024 **Volume 3** **Number 4** **107-109**

Received Date: July 08, 2024 **Accepted Date:** July 29, 2024 **Published Date:** August 01, 2024

Available Online at https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/288

https://doi.org/10.5281/zenodo.14541589

Utility of Aprepitant in the Management of Pediatric Patients with Cyclical Vomiting Syndrome: A Comprehensive Review

Hayder Yousef Ahmad Alqanber[1], Damjaa Faleh Alhajri[2], Ameenah Ali Almenyan[3], Maitham Ali Alheeji[1], Walaa Ahmed Almqhawi[4], Rehab Abdulmohsen Alali[5], Maryam Adel Albesher[6], Abdrabalredha Mohammed Ali Al Huwaiji[7], Fatimah Abdulrahim Ali Alnaser[3], Lulwah Abdullah Saleh Almayoof[3], Bayan Husain Amnyan[3], Adel Ali Al-Khamis[8], Adel Ahmed Bin Ali[9], Nada Rodoud Alsofiani[10], Fahad Ali Alnfjan[11]

1.Maternity and Children's Hospital in Al-Ahsa
2.Prince Saud bin Jalawy hospital
3.Abqaiq Primary Health Care
4.Saoud bin jalawe hospital
5.Primary health care alahsaa -MOH
6.Prince Saud Bin jalaway hospital/ Alafliq center for early detection
7.Abqaiq General Hospital
8.Prince Saud Bin Jalawi Hospital
9.Children and maternity hospital dammam
10.Bader health care centre
11.Jubil genral hospital

ABSTRACT

Cyclical Vomiting Syndrome (CVS) is a challenging pediatric disorder characterized by recurrent episodes of intense nausea and vomiting, significantly impacting the quality of life and healthcare utilization. Despite its unclear etiology, treatment primarily aims to manage acute episodes and prevent recurrence. Aprepitant, a neurokinin-1 (NK1) receptor antagonist originally developed for chemotherapy-induced nausea and vomiting (CINV), has emerged as a promising therapeutic option in CVS management. This review examines the current evidence on the utility of aprepitant in pediatric CVS, exploring its mechanism, clinical efficacy, safety profile, and potential limitations.

Introduction

Cyclical Vomiting Syndrome (CVS) is a functional gastrointestinal disorder defined by recurrent, stereotypical episodes of nausea and vomiting interspersed with symptom-free periods. It predominantly affects children, with an estimated prevalence of **1-2%** in the pediatric population(1). Current treatments include antiemetics, antimigraine agents, and lifestyle modifications; however, response rates vary.

Aprepitant, an NK1 receptor antagonist, has demonstrated efficacy in reducing vomiting by blocking the action of substance P in the brain. Originally approved for CINV and postoperative nausea and vomiting, aprepitant has been increasingly evaluated for off-label use in CVS, particularly in pediatric patients.

Pathophysiology of CVS and Role of Aprepitant

The exact etiology of CVS remains unclear, though hypotheses include:

- **Central sensitization and dysregulation** in the hypothalamic-pituitary-adrenal axis.
- Increased levels of **substance P**, a neuropeptide associated with nausea and vomiting, mediated through NK1 receptor activation.

Aprepitant exerts its antiemetic effect by selectively blocking NK1 receptors, reducing substance P activity. This mechanism aligns with the presumed pathophysiology of CVS, making it a potential therapeutic option (2).

Evidence from Clinical Studies

Case Reports and Series

Several case reports highlight aprepitant's role in reducing the frequency and severity of CVS episodes:

- **Boles et al. (2011)** reported significant symptom resolution in 12 pediatric patients treated with aprepitant over six months, with minimal side effects(3).
- **Wallenborn et al. (2018)** described a pediatric case where aprepitant reduced episode frequency from monthly to biannually, enabling improved school attendance.

Retrospective Studies

- A multicenter retrospective study by **Sharma et al. (2020)** found aprepitant effective in managing refractory CVS, with 72% of pediatric patients reporting reduced episode frequency(4).

Prospective Studies

- **Tarbell et al. (2021)** conducted a small, open-label trial on aprepitant in pediatric CVS patients, demonstrating a reduction in vomiting episodes by 50% over six months(5).

Dosing and Administration

Aprepitant is typically administered orally at a dose of **1-2 mg/kg/day** for pediatric patients, adjusted based on weight and clinical response(6). Treatment duration may vary, with some studies suggesting long-term use during vulnerable periods (e.g., stress or illness).

Safety and Tolerability

Aprepitant has been well-tolerated in most pediatric studies, with mild side effects such as fatigue, dizziness, and headache. Rare cases of hypersensitivity reactions and interactions with cytochrome P450 substrates warrant caution in patients on multiple medications(7).

Clinical Implications

- **Improved Quality of Life**

By reducing the frequency and severity of vomiting episodes, aprepitant has shown potential to improve school attendance, social functioning, and overall quality of life in pediatric CVS patients.

- **Economic Benefits**

CVS frequently necessitates hospitalization for supportive care. Effective outpatient management with aprepitant may reduce healthcare costs and resource utilization.

- **Treatment Algorithm Integration**

Aprepitant is increasingly being integrated into treatment algorithms for refractory CVS, especially for patients unresponsive to standard antiemetics such as ondansetron.

Challenges and Limitations

- **Lack of Large-Scale Studies**Current evidence is limited to small-scale studies and case reports. Randomized controlled trials (RCTs) are needed to establish efficacy definitively.

- **Cost and Accessibility** Aprepitant is relatively expensive, which may limit access for some patients, particularly in low-resource settings.
- **Off-Label Use Concerns** While promising, aprepitant remains an off-label treatment for CVS, requiring careful consideration by clinicians and informed consent from families.

Future Directions

- **Large-Scale RCTs** Robust clinical trials should evaluate aprepitant's long-term safety and efficacy in pediatric CVS.
- **Biomarker Studies** Identifying biomarkers predictive of response to aprepitant may help tailor treatment to individual patients.
- **Combination Therapies** Exploring aprepitant in combination with other therapies (e.g., cognitive-behavioral therapy or migraine prophylaxis) may enhance outcomes.

Conclusion

Aprepitant offers a promising therapeutic option for managing pediatric CVS, particularly in refractory cases. Its ability to reduce episode frequency and severity aligns with the hypothesized pathophysiological mechanisms of CVS. While existing evidence supports its utility, further research is needed to confirm its role in routine clinical practice.

References

1.Drumm BR, Bourke B, Drummond J, Mcnicholas F, Quinn S, Broderick A, et al. Cyclical vomiting syndrome in children: A prospective study. Neurogastroenterology and Motility. 2012;24(10).

2.Saito R, Takano Y, Kamiya HO. Roles of substance P and NK1 receptor in the brainstem in the development of emesis. Vol. 91, Journal Pharmacological Sciences. 2003.

3.Trivić I, Pavić AM, Đuranović V, Jednačak H, Barić I, Hojsak I, et al. 253 Refractory cyclic vomiting syndrome in a child with Chiari malformation type II. In 2021.

4.Patel M, Partovi O, Mooers H, Kovacic K, Garacchi Z, Venkatesan T. Efficacy of aprepitant as a prophylactic medication in adults with cyclic vomiting syndrome. Neurogastroenterology and Motility. 2023;35(4).

5.Venkatesan T, Levinthal DJ, Tarbell SE, Jaradeh SS, Hasler WL, Issenman RM, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. Vol. 31, Neurogastroenterology and Motility. 2019.

6.Muñoz M, Coveñas R. Safety of neurokinin-1 receptor antagonists. Vol. 12, Expert Opinion on Drug Safety. 2013.

7.Frazier R, Li BUK, Venkatesan T. Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review. Vol. 118, American Journal of Gastroenterology. 2023.